- Processing Solutions
- White Papers
- Tech Portals
- Buyer's Guide
LONDON — Britain’s National Institute for Health and Clinical Excellence recommended Friday that Bristol-Myers Squibb Co.’s skin-cancer treatment Yervoy not be used due to uncertainty about the product’s longer-term benefits, its side effects and its cost, MarketWatch reported.
The draft guidance on the medicine is now open for consultation until Nov. 4 before further decisions on the therapy are made.
The drug is intended to help patients with advanced melanoma live longer.